273 related articles for article (PubMed ID: 25796338)
1. Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica.
Gonzalez P; Hildesheim A; Herrero R; Katki H; Wacholder S; Porras C; Safaeian M; Jimenez S; Darragh TM; Cortes B; Befano B; Schiffman M; Carvajal L; Palefsky J; Schiller J; Ocampo R; Schussler J; Lowy D; Guillen D; Stoler MH; Quint W; Morales J; Avila C; Rodriguez AC; Kreimer AR;
Vaccine; 2015 Apr; 33(18):2141-51. PubMed ID: 25796338
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
Porras C; Tsang SH; Herrero R; Guillén D; Darragh TM; Stoler MH; Hildesheim A; Wagner S; Boland J; Lowy DR; Schiller JT; Schiffman M; Schussler J; Gail MH; Quint W; Ocampo R; Morales J; Rodríguez AC; Hu S; Sampson JN; Kreimer AR;
Lancet Oncol; 2020 Dec; 21(12):1643-1652. PubMed ID: 33271093
[TBL] [Abstract][Full Text] [Related]
3. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.
Kreimer AR; González P; Katki HA; Porras C; Schiffman M; Rodriguez AC; Solomon D; Jiménez S; Schiller JT; Lowy DR; van Doorn LJ; Struijk L; Quint W; Chen S; Wacholder S; Hildesheim A; Herrero R;
Lancet Oncol; 2011 Sep; 12(9):862-70. PubMed ID: 21865087
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.
Herrero R; Hildesheim A; Rodríguez AC; Wacholder S; Bratti C; Solomon D; González P; Porras C; Jiménez S; Guillen D; Morales J; Alfaro M; Cyr J; Morrisey K; Estrada Y; Cortés B; Morera LA; Freer E; Schussler J; Schiller J; Lowy D; Schiffman M;
Vaccine; 2008 Sep; 26(37):4795-808. PubMed ID: 18640170
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.
Kreimer AR; Struyf F; Del Rosario-Raymundo MR; Hildesheim A; Skinner SR; Wacholder S; Garland SM; Herrero R; David MP; Wheeler CM; ; González P; Jiménez S; Lowy DR; Pinto LA; Porras C; Rodriguez AC; Safaeian M; Schiffman M; Schiller JT; Schussler J; Sherman ME; ; Bosch FX; Castellsague X; Chatterjee A; Chow SN; Descamps D; Diaz-Mitoma F; Dubin G; Germar MJ; Harper DM; Lewis DJ; Limson G; Naud P; Peters K; Poppe WA; Ramjattan B; Romanowski B; Salmeron J; Schwarz TF; Teixeira JC; Tjalma WA; ;
Lancet Oncol; 2015 Jul; 16(7):775-86. PubMed ID: 26071347
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.
Tota JE; Struyf F; Sampson JN; Gonzalez P; Ryser M; Herrero R; Schussler J; Karkada N; Rodriguez AC; Folschweiller N; Porras C; Schiffman M; Schiller JT; Quint W; Kreimer AR; Wheeler CM; Hildesheim A;
J Natl Cancer Inst; 2020 Aug; 112(8):818-828. PubMed ID: 31697384
[TBL] [Abstract][Full Text] [Related]
8. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
9. Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies.
Kreimer AR; Herrero R; Sampson JN; Porras C; Lowy DR; Schiller JT; Schiffman M; Rodriguez AC; Chanock S; Jimenez S; Schussler J; Gail MH; Safaeian M; Kemp TJ; Cortes B; Pinto LA; Hildesheim A; Gonzalez P;
Vaccine; 2018 Aug; 36(32 Pt A):4774-4782. PubMed ID: 29366703
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial.
Porras C; Sampson JN; Herrero R; Gail MH; Cortés B; Hildesheim A; Cyr J; Romero B; Schiller JT; Montero C; Pinto LA; Schussler J; Coronado K; Sierra MS; Kim JJ; Torres CM; Carvajal L; Wagner S; Campos NG; Ocampo R; Kemp TJ; Zuniga M; Lowy DR; Avila C; Chanock S; Castrillo A; Estrada Y; Barrientos G; Monge C; Oconitrillo MY; Kreimer AR
Vaccine; 2022 Jan; 40(1):76-88. PubMed ID: 34857420
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials.
Tota JE; Struyf F; Merikukka M; Gonzalez P; Kreimer AR; Bi D; Castellsagué X; de Carvalho NS; Garland SM; Harper DM; Karkada N; Peters K; Pope WAJ; Porras C; Quint W; Rodriguez AC; Schiffman M; Schussler J; Skinner SR; Teixeira JC; Wheeler CM; Herrero R; Hildesheim A; Lehtinen M;
J Natl Cancer Inst; 2017 Jan; 109(7):. PubMed ID: 28132019
[TBL] [Abstract][Full Text] [Related]
13. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,
Bratti MC; Rodríguez AC; Schiffman M; Hildesheim A; Morales J; Alfaro M; Guillén D; Hutchinson M; Sherman ME; Eklund C; Schussler J; Buckland J; Morera LA; Cárdenas F; Barrantes M; Pérez E; Cox TJ; Burk RD; Herrero R
Rev Panam Salud Publica; 2004 Feb; 15(2):75-89. PubMed ID: 15030652
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial.
Kreimer AR; Sampson JN; Porras C; Schiller JT; Kemp T; Herrero R; Wagner S; Boland J; Schussler J; Lowy DR; Chanock S; Roberson D; Sierra MS; Tsang SH; Schiffman M; Rodriguez AC; Cortes B; Gail MH; Hildesheim A; Gonzalez P; Pinto LA;
J Natl Cancer Inst; 2020 Oct; 112(10):1038-1046. PubMed ID: 32091594
[TBL] [Abstract][Full Text] [Related]
15. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
Castellsagué X; Schneider A; Kaufmann AM; Bosch FX
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S15-23. PubMed ID: 19819540
[TBL] [Abstract][Full Text] [Related]
16. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
17. Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial.
Hu SY; Kreimer AR; Porras C; Guillén D; Alfaro M; Darragh TM; Stoler MH; Villegas LF; Ocampo R; Rodriguez AC; Schiffman M; Tsang SH; Lowy DR; Schiller JT; Schussler J; Quint W; Gail MH; Sampson JN; Hildesheim A; Herrero R;
J Natl Cancer Inst; 2022 Sep; 114(9):1253-1261. PubMed ID: 35640980
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of HPV vaccination in women reaching screening age in Italy.
Carozzi FM; Ocello C; Burroni E; Faust H; Zappa M; Paci E; Iossa A; Bonanni P; Confortini M; Sani C
J Clin Virol; 2016 Nov; 84():74-81. PubMed ID: 27728850
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial.
Sierra MS; Tsang SH; Hu S; Porras C; Herrero R; Kreimer AR; Schussler J; Boland J; Wagner S; Cortes B; Rodríguez AC; Quint W; van Doorn LJ; Schiffman M; Sampson JN; Hildesheim A;
J Infect Dis; 2021 Aug; 224(3):503-516. PubMed ID: 33326576
[TBL] [Abstract][Full Text] [Related]
20. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
